TCR2 Therapeutics Inc. - Common Stock (NQ:TCRR)

N/A UNCHANGED

Last Price Updated: 4:00 PM EDT, May 31, 2023 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about TCR2 Therapeutics Inc. - Common Stock

< Previous 1 2 3 4 Next >

Esperion Therapeutics And 2 Other Stocks Under $3 Insiders Are Aggressively Buying ↗

May 11, 2023

The Dow Jones closed slightly lower on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in...

Via Benzinga

Recap: TCR2 Therapeutics Q1 Earnings ↗

May 11, 2023

Via Benzinga

TCR² Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

May 11, 2023

From TCR2 Therapeutics

Via GlobeNewswire

TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 08, 2023

From TCR2 Therapeutics

Via GlobeNewswire

What To Know About Jefferies's Downgrade of TCR2 Therapeutics ↗

March 09, 2023

Via Benzinga

4 Analysts Have This to Say About TCR2 Therapeutics ↗

March 09, 2023

Via Benzinga

Adaptimmune Agrees To Merge With Another Cell Therapy Focused Company ↗

March 06, 2023

Via Benzinga

Ribbon Communications And 2 Other Stocks Under $3 Insiders Are Aggressively Buying ↗

May 08, 2023

The Dow Jones jumped more than 500 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in...

Via Benzinga

TCR² THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of TCR² Therapeutics Inc. - TCRR

April 26, 2023

From Kahn Swick & Foti, LLC

Via Business Wire

TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

April 03, 2023

From TCR2 Therapeutics

Via GlobeNewswire

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Diffusion Pharmaceuticals Inc. (Nasdaq- DFFN), U.S. Xpress Enterprises, Inc. (NYSE – USX), TCR² Therapeutics Inc. (Nasdaq – TCRR), Costar Technologies, Inc. (OTC –

March 30, 2023

From Brodsky & Smith LLC

Via GlobeNewswire

Benzinga's Top Ratings Upgrades, Downgrades For March 24, 2023 ↗

March 24, 2023

Via Benzinga

TCR² Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Update

March 23, 2023

From TCR2 Therapeutics

Via GlobeNewswire

Benzinga's Top Ratings Upgrades, Downgrades For March 9, 2023 ↗

March 09, 2023

Via Benzinga

TCR² THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of TCR² Therapeutics Inc. - TCRR

March 08, 2023

From Kahn Swick & Foti, LLC

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For March 8, 2023 ↗

March 08, 2023

Via Benzinga

Health Care ETFs Have Lost In The Last Month - These Top Pharma Stocks Are The Reason ↗

March 07, 2023

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For March 7, 2023 ↗

March 07, 2023

Via Benzinga

Why Is TCR2 Therapeutics Stock Trading Higher Today? ↗

March 06, 2023

TCR² Therapeutics (NASDAQ: TCRR) shares are trading higher on Monday after the company and Adaptimmune Therapeutics (NASDAQ: ADAP) announced an agreement under which the two companies will combine to...

Via Benzinga

Why Aclaris Therapeutics Shares Are Trading Lower By Around 55%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

March 06, 2023

Gainers Unicycive Therapeutics, Inc. (NASDAQ: UNCY) shares surged 159% to $1.27 after the company announced a private placement of up to $130 million in gross proceeds to commercialize and launch...

Via Benzinga

12 Health Care Stocks Moving In Monday's Intraday Session ↗

March 06, 2023

Via Benzinga

TCR2 Therapeutics (NASDAQ: TCRR) and Adaptimmune Therapeutics (NASDAQ: ADAP) Announce Strategic Merger to Leverage Technologies and Create a New Major Cell Therapy Company

March 06, 2023

TCR2 Therapeutics, Inc. (NASDAQ: TCRR) operates as a clinical-stage immunotherapy company, which is focused on the research and development of

Via Spotlight Growth

Why Is TCR2 Therapeutics (TCRR) Stock Up 30% Today? ↗

March 06, 2023

A new deal offers a lifeline for TCRR stock and a compatible investment for Adaptimmune. Both companies are targeting solid cancer tumors.

Via InvestorPlace

TCRR Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of TCR² Therapeutics Inc. Is Fair to Shareholders

March 06, 2023

From Halper Sadeh LLC

Via Business Wire

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

March 06, 2023

Via Benzinga

Adaptimmune and TCR2 Therapeutics Announce Strategic Combination to Create a Preeminent Cell Therapy Company for Solid Tumors

March 06, 2023

Compelling clinical data with clear paths to products and multiple near‐term value-creating catalystsComplementary technology platforms designed to treat solid tumors...

Via Newsfile

Adaptimmune and TCR² Therapeutics Announce Strategic Combination to Create a Preeminent Cell Therapy Company for Solid Tumors

March 06, 2023

From TCR2 Therapeutics

Via GlobeNewswire

TCR² Therapeutics to Present at SVB Securities Global Biopharma Conference 2023

February 08, 2023

From TCR2 Therapeutics

Via GlobeNewswire

CRISPR Layoffs 2023: Job Cuts Hit Gene-Editing Stocks FATE, TCRR, IPSC ↗

January 06, 2023

Gene-editing stocks have not been immune when it comes to job losses and workforce reductions. Here are a few of the latest.

Via InvestorPlace

Why Spruce Biosciences Shares Are Trading Higher By 100%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗

January 06, 2023

Gainers Swvl Holdings Corp. (NASDAQ: SWVL) surged 133% to $0.3218. Swvl recently announced the commencement of a strategic review process.

Via Benzinga

< Previous 1 2 3 4 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.